Disclosure! These peptides have not been evaluated by the FDA. These peptides are not a form of medication and are for research purposes only. Purchasing research peptides for personal use is illegal.

CJC-1295, also known as DAC:GRF (short for drug affinity complex:growth hormone-releasing factor), is a synthetic analogue of growth hormone-releasing hormone (GHRH) (also known as growth hormone-releasing factor (GRF)) and a growth hormone secretagogue (GHS) which was developed by ConjuChem Biotechnologies.^[1][2][3] It is a modified form of GHRH (1-29) with improved pharmacokinetics, especially in regard to half-life.^[1][2][3][4]

CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans.^[1][2][3][5] With a single injection, in human subjects, CJC-1295 increases plasma GH levels by 2- to 10-fold for 6 days or longer and plasma IGF-1 levels by 0.5- to 3-fold for 9 to 11 days.^[3] The drug has an estimated half-life of about 6 to 8 days in humans.^[3] With multiple doses of CJC-1295, IGF-1 levels were found to remain elevated in humans for up to 28 days.^[3]

CJC-1295 has been shown to extend the half-life and bioavailability of growth-hormone-releasing hormone 1-29 and stimulate insulin-like growth factor 1 secretion. It increases the half-life of acting agents by bioconjugation.^[6] The extended half-life is achieved through the addition of a drug affinity complex (DAC) that binds to albumin, thus prolonging the peptide’s presence in the bloodstream.^[7][8][9] It is primarily used for its potential to stimulate the release of growth hormone (GH) from the pituitary gland.

CJC-1295 – Wikipedia

Lyophilized powder form, intended solely for laboratory use and not for human consumption.